Jhawar Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 1.47 M
- Company Age 31 Year, 1 Month
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 12.05 Cr
- Revenue Growth -97.77%
- Profit Growth -802.75%
- Ebitda -4.12%
- Net Worth -0.26%
- Total Assets -0.69%
About Jhawar Biotech
Jhawar Biotech Pvt Ltd (JBPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 January 1994 and has a history of 31 years and one month. Its registered office is in Surat, Gujarat, India.
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.47 M.
The company currently has active open charges totaling ₹12.05 Cr.
Jugalkishor Jhawar and Saritadevi Jhawar serve as directors at the Company.
Company Details
- Location
Surat, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U01110GJ1994PTC021083
- Company No.
021083
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 1994
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Jhawar Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jugalkishor Jhawar  | Director | 19-Jan-1994 | Current |
| Saritadevi Jhawar | Director | 27-Mar-2013 | Current |
Financial Performance of Jhawar Biotech.
Jhawar Biotech Pvt Ltd, for the financial year ended 2019, experienced significant reduction in revenue, with a 97.77% decrease. The company also saw a substantial fall in profitability, with a 802.75% decrease in profit. The company's net worth dipped by a decrease of 0.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jhawar Biotech?
In 2019, Jhawar Biotech had a promoter holding of 85.49% and a public holding of 14.52%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Supreme Avenues Private LimitedJugalkishor Jhawar and Saritadevi Jhawar are mutual person
Charges (Loans)
₹120.50 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 12.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Oct 2001 | Canara Bank | ₹5.50 M | Open |
| 18 Sep 2001 | Canara Bank | ₹11.50 Cr | Open |
How Many Employees Work at Jhawar Biotech?
Unlock and access historical data on people associated with Jhawar Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jhawar Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jhawar Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
